Short course radical cure of P. vivax in Nepal - a randomized controlled trial – pilot study (SIRIN)

Aims and objectives

To simplify malaria treatment in Nepal by reducing the treatment course of primaquine radical cure for P. vivax malaria.

The study will assess the safety and efficacy of a low dose, short course primaquine (3.5mg/kg total dose given over 7 days) treatment in glucose-6-phosphate dehydrogenase (G6PD) normal patients with P. vivax and P. falciparum to reduce the risk of subsequent P. vivax episodes.

Visit Menzies school of health research for more information.